Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 172INDUSTRY 89OTHER_GOV 4UNKNOWN 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Extranodal NK-T-Cell 2

Interventions

Paclitaxel 20Capecitabine 18S 1 (combination) 17Cisplatin 15Oxaliplatin 11apatinib 8Radiotherapy, Intensity-Modulated 8Epirubicin 8Docetaxel 8Carboplatin 8Radiotherapy 7Irinotecan 7titanium silicide 6sintilimab 6pyrotinib 6nimotuzumab 6anlotinib 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6nedaplatin 5camrelizumab 5Temozolomide 5Etoposide 5Drug Therapy 5Bevacizumab 5nabiximols 4Vinorelbine 4Trastuzumab 4Radiation Dose Hypofractionation 4Pemetrexed 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
UNKNOWN × Interventional × spartalizumab × Clear all
NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

ChineseAMS

Phase 2 Unknown
54 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT05149170 2021-12-08

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

ChineseAMS

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡